publication . Article . 2020

COVID-19 Pneumonia in Patients with Chronic Myocarditis (HBV-Associated with InfarctLike Debute): Specifics of the Diseases Course, the Role of the Basic Therapy (Part II)

O. V. Blagova; N. V. Varionchik; M. M. Beraia; V. A. Zaidenov; E. A. Kogan; N. D. Sarkisova; Nedostup Av;
Open Access
  • Published: 04 Nov 2020 Journal: Rational Pharmacotherapy in Cardiology, volume 16, pages 730-736 (issn: 1819-6446, eissn: 2225-3653, Copyright policy)
  • Publisher: Stolichnaya Izdatelskaya Kompaniyaizdat
<jats:p>Chronic infectious-immune myocarditis of severe course can potentially be considered as a factor that aggravates the course of new coronavirus disease (COVID-19) and increases the risk of adverse outcomes. The interaction of chronic myocarditis and COVID-19 during long-term immunosuppressive therapy has not been studied. We present a description of a 35-year-old female patient with chronic infectious-immune myocarditis (morphologically confirmed, with a history of infarction-like onset and thromboembolic complications), who had continuous immunosuppressive therapy with methylprednisolone and mycophenolate mofetil. The patient also received new oral antic...
Persistent Identifiers
free text keywords: covid-19, chronic myocarditis, bilateral pneumonia, immunosuppressive therapy, corticosteroids, mycophenolate mofetil, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701, Hydroxychloroquine, medicine.drug, medicine, Coronavirus, medicine.disease_cause, Heart failure, medicine.disease, Myocarditis, Respiratory failure, Levofloxacin, Methylprednisolone, Exacerbation, business.industry, business, Internal medicine, medicine.medical_specialty
Any information missing or wrong?Report an Issue